Literature DB >> 11328953

Increased frequency of alleles associated with elevated tumor necrosis factor-alpha levels in children with Kawasaki disease.

M W Quasney1, D E Bronstein, R M Cantor, Q Zhang, C Stroupe, H Shike, J F Bastian, T Matsubara, M Fujiwara, K Akimoto, J W Newburger, J C Burns.   

Abstract

Genetic polymorphisms influence the magnitude of the cytokine response after an inflammatory stimulus. To determine whether such polymorphisms might play a role in Kawasaki disease (KD), we analyzed white and Japanese children with KD and control populations for two polymorphic loci in which the A allele is associated with high tumor necrosis factor-alpha secretion. The lymphotoxin-alpha+250 A/A genotype was overrepresented among white children with KD compared with controls (0.59 versus 0.36; p = 0.013). The tumor necrosis factor-alpha-308 A/G genotype was overrepresented among whites with KD who had coronary artery abnormalities compared with those with normal echocardiograms (0.36 versus 0.09; p = 0.044). No significant difference was seen at either locus between Japanese children with KD and Japanese controls. The increased frequency of the high secretor alleles in white children with KD suggests that these loci may be related to susceptibility to KD and to outcome after disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328953     DOI: 10.1203/00006450-200105000-00013

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  20 in total

1.  Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease.

Authors:  Jane C Burns; Chisato Shimizu; Enrique Gonzalez; Hemant Kulkarni; Sukeshi Patel; Hiroko Shike; Robert S Sundel; Jane W Newburger; Sunil K Ahuja
Journal:  J Infect Dis       Date:  2005-06-08       Impact factor: 5.226

Review 2.  Genetic polymorphisms in Kawasaki disease.

Authors:  Ho-chang Kuo; Wei-chiao Chang
Journal:  Acta Pharmacol Sin       Date:  2011-09-05       Impact factor: 6.150

3.  Ventricular repolarization lability in children with Kawasaki disease.

Authors:  Marina Kuriki; Masayuki Fujino; Ken-ichi Tanaka; Kayo Horio; Hirofumi Kusuki; Misa Hosoi; Yoshihiko Eryu; Tomochika Kato; Toshio Yamazaki; Tadayoshi Hata
Journal:  Pediatr Cardiol       Date:  2011-02-23       Impact factor: 1.655

Review 4.  Inflammation as a risk factor for myocardial infarction.

Authors:  Toshihiro Tanaka; Kouichi Ozaki
Journal:  J Hum Genet       Date:  2006-06-13       Impact factor: 3.172

5.  Family-based association analysis implicates IL-4 in susceptibility to Kawasaki disease.

Authors:  J C Burns; C Shimizu; H Shike; J W Newburger; R P Sundel; A L Baker; T Matsubara; Y Ishikawa; V A Brophy; S Cheng; M A Grow; L L Steiner; N Kono; R M Cantor
Journal:  Genes Immun       Date:  2005-08       Impact factor: 2.676

6.  Two cases of Kawasaki disease with hidden neuroblastoma.

Authors:  Yun Ju Lim; Jo Won Jung; Hyun Joo Jung; Jun Eun Park
Journal:  Indian J Pediatr       Date:  2012-12-19       Impact factor: 1.967

7.  The association between transforming growth factor-beta gene promoter C-509T polymorphism and Chinese children with Henoch-Schönlein purpura.

Authors:  Yao-Hsu Yang; Huey-Jen Lai; Cheng-Kai Kao; Yu-Tsan Lin; Bor-Luen Chiang
Journal:  Pediatr Nephrol       Date:  2004-07-15       Impact factor: 3.714

Review 8.  Kawasaki disease.

Authors:  Dong Soo Kim
Journal:  Yonsei Med J       Date:  2006-12-31       Impact factor: 2.759

9.  Interleukin-18 gene 105A/C genetic polymorphism is associated with the susceptibility of Kawasaki disease.

Authors:  Shih-Yin Chen; Lei Wan; Yu-Chuen Huang; Jim Jinn-Chyuan Sheu; Yu-Ching Lan; Chih-Ho Lai; Cheng-Wen Lin; Jeng Sheng Chang; Yuhsin Tsai; Shih-Ping Liu; Ying-Ju Lin; Fuu-Jen Tsai
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

10.  Giant coronary artery aneurysm formation following meningococcal septicaemia.

Authors:  S R Ford; A Rao; L Kochilas
Journal:  Pediatr Cardiol       Date:  2007-05-05       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.